(4-硝基咪唑-1-基)乙酸甲酯 | 13230-21-2

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (4-硝基咪唑-1-基)乙酸甲酯
• 中文别名: (4-硝基-1-咪唑基)乙酸甲酯
• 英文名称: (4-nitro-imidazol-1-yl)-acetic acid methyl ester
• 英文别名: methyl 2-(4-nitro-1H-imidazol-1-yl)acetate；methyl 2-(4-nitro-1H-1-imidazolyl)acetate；(4-nitroimidazol-1-yl)acetic acid methyl ester；Methyl (4-nitro-1-imidazolyl)acetate；methyl 2-(4-nitroimidazol-1-yl)acetate
• CAS: 13230-21-2
• 化学式: C₆H₇N₃O₄
• 分子量: 185.139
• InChiKey: LCKCAKPRNOIOBA-UHFFFAOYSA-N

物化性质

• 熔点：
  143-147 °C

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  89.9
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26
• 危险类别码：
  R36/37/38
• 海关编码：
  2933290090
• WGK Germany：
  3

反应信息

• 作为反应物：
  描述：

  (4-硝基咪唑-1-基)乙酸甲酯 在 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 20.0 ℃ 、275.8 kPa 条件下， 生成 (4-amino-imidazol-1-yl)-acetic acid methyl ester
  参考文献：
  名称：

  二酰胺氨基咪唑：一系列新型的γ-分泌酶抑制剂，用于治疗阿尔茨海默氏病

  摘要：

  描述了衍生自DAPT修饰的一系列新型二取代咪唑的合成及其构效关系（SAR）。随后的优化导致鉴定出一系列高效抑制剂，这些抑制剂在咪唑侧链中包含β-胺，可导致豚鼠体内血浆和大脑Aβ大量降低。研究了化合物10h的Aβ减少与B细胞群变化之间的治疗指数。

  DOI：

  10.1016/j.bmcl.2010.12.117
• 作为产物：
  描述：

  4-硝基-3H-咪唑 、 氯乙酸甲酯 在 四丁基碘化铵 、 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 0.5h， 以78%的产率得到(4-硝基咪唑-1-基)乙酸甲酯
  参考文献：
  名称：

  Design and Synthesis of Heterocyclic Hydroxamic Acid Derivatives as Inhibitors ofHelicobacterpyloriUrease

  摘要：

  Helicobacter pylori produces ammonia to help counter the acidic environment in the human stomach. The production of ammonia, essential for the microorganism's survival and virulence, is the product of enzymatic conversion of urea by the H. pylori's urease. Inhibition of urease activity by dipeptide hydroxamic acids has previously been demonstrated using a variety of fluorides, thiols and hydroxamic acids. Studies employing computer-aided drug design techniques have been utilized to suggest a novel series of heterocyclic hydroxamic acid derivatives as potential as urease inhibitors. The heterocyclic compounds 7a,b, 10b, 12b, 16b, and 19b have been designed, synthesized, and preliminarily tested as dipeptide mimics which offer a structure that is more biologically stable than that of the reported dipeptide inhibitors.

  DOI：

  10.1081/scc-120021024

文献信息

• Nitroimidazoles, XIV: Synthesis of 4-Nitroimidazoles with 1-Substituents Containing Acid, Ester or Phenol Functions, and Radiosensitizing Efficiency of Some of These Compounds
  作者：Jerzy Suwinski、Wojciech Szczepankiewicz、Maria Widel

  DOI：10.1002/ardp.19923250602

  日期：——

  1, 4‐Dinitroimidazole and 1, 4‐dinitro‐2‐methylimidazole were reacted with aminocarboxylic acids and their esters, aminosulfonic acids, and aminophenol to obtain the corresponding 1‐substituted‐4‐nitroimidazoles. The radiosensitizing efficiency of some esters of 2‐(4‐nitro‐1‐imidazolyl)alkanecarboxylic acids was tested.

  1, 4-二硝基咪唑和1, 4-二硝基-2-甲基咪唑与氨基羧酸及其酯、氨基磺酸、氨基苯酚反应得到相应的1-取代-4-硝基咪唑。测试了某些 2-（4-硝基-1-咪唑基）烷烃羧酸酯的放射增敏效率。
• Imidazole compounds for the treatment of neurological disorders
  申请人：Brodney A. Michael

  公开号：US20070066613A1

  公开（公告）日：2007-03-22

  The present invention relates to compounds of Formula I wherein R 1 , R 2 , R 3 , R 4 , R 6 , R 7 and A are as defined. Compounds of Formula I have activity inhibiting production of Aβ-peptide. The invention also relates to pharmaceutical compositions and methods for treating diseases and disorders, for example, neurodegenerative and/or neurological disorders, e.g., Alzheimer's disease, in a mammal comprising compounds of Formula I.

  本发明涉及公式I中的化合物，其中R1、R2、R3、R4、R6、R7和A如定义。公式I的化合物具有抑制Aβ肽产生活性。该发明还涉及包含公式I化合物的药物组合物和治疗疾病和紊乱的方法，例如在哺乳动物中治疗神经退行性和/或神经系统疾病，例如阿尔茨海默病。
• [EN] IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS<br/>[FR] COMPOSES D'IMIDAZOLE DESTINES AU TRAITEMENT DE TROUBLES NEURODEGENERATIFS
  申请人：PFIZER PROD INC

  公开号：WO2005092864A1

  公开（公告）日：2005-10-06

  The present invention relates to compounds of the Formula (I) wherein R1, R2, R3, R4, R5, R6, R7 and A are as defined. Compounds of the Formula (I) have activity inhibiting production of Aβ-peptide. The invention also relates to pharmaceutical compositions and methods for treating diseases and disorders, for example, neurodegenerative and/or neurological disorders, e.g., Alzheimer’s disease, in a mammal comprising compounds of the Formula (I).

  本发明涉及式(I)的化合物，其中R1、R2、R3、R4、R5、R6、R7和A的定义如上所述。式(I)的化合物具有抑制Aβ肽产生的活性。本发明还涉及制药组合物和治疗疾病和障碍的方法，例如，神经退行性和/或神经系统疾病，例如阿尔茨海默病，在哺乳动物中包括式(I)的化合物。
• Imidazole compounds for the treatment of neurodegenerative disorders
  申请人：Brodney A. Michael

  公开号：US20050215610A1

  公开（公告）日：2005-09-29

  The present invention relates to compounds of the Formula I wherein R 1 , R 2 , R 3 , R 4 , R 6 , R 7 and A are as defined. Compounds of the Formula I have activity inhibiting production of Aβ-peptide. The invention also relates to pharmaceutical compositions and methods for treating diseases and disorders, for example, neurodegenerative and/or neurological disorders, e.g., Alzheimer's disease, in a mammal comprising compounds of the Formula I.

  本发明涉及公式I中的化合物，其中R1、R2、R3、R4、R6、R7和A的定义如所述。公式I的化合物具有抑制Aβ肽生成活性。本发明还涉及制备包含公式I化合物的药物组合物以及治疗哺乳动物的疾病和障碍的方法，例如神经退行性和/或神经系统疾病，例如阿尔茨海默病。
• IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
  申请人：Brodney Michael A.

  公开号：US20080227781A1

  公开（公告）日：2008-09-18

  The present invention relates to compounds of the Formula I wherein R 1 , R 2 , R 3 , R 4 , R 6 , R 7 and A are as defined. Compounds of the Formula I have activity inhibiting production of Aβ-peptide. The invention also relates to pharmaceutical compositions and methods for treating diseases and disorders, for example, neurodegenerative and/or neurological disorders, e.g., Alzheimer's disease, in a mammal comprising compounds of the Formula I.

  本发明涉及式I的化合物，其中R1、R2、R3、R4、R6、R7和A的定义如所述。式I的化合物具有抑制Aβ-肽产生的活性。本发明还涉及含有式I化合物的药物组合物以及治疗哺乳动物的疾病和障碍的方法，例如神经退行性和/或神经系统疾病，例如阿尔茨海默病。